on Nyxoah SA. (isin : BE0974358906)
Nyxoah Reports Third Quarter 2024 Financial Results
On November 6, 2024, Nyxoah SA released its third-quarter financial results, highlighting a 30% increase in sales compared to the same period last year, reaching €1.3 million. The company, focused on developing neuromodulation treatments for Obstructive Sleep Apnea (OSA), is preparing for a U.S. commercial launch upon anticipated FDA approval in the first quarter of 2025.
Key achievements include raising €24.6 million to extend its cash runway until mid-2026 and strengthening its U.S. team with new leadership. Despite increased expenses from research and development and commercial activities, Nyxoah maintains a solid cash position of €71.0 million, demonstrating financial resilience as it advances towards potential U.S. market entry.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nyxoah SA. news